Rank: 4 | Score: 78/100
Tau Interception Using Conformational-Selective Extracellular Traps is a therapeutic strategy that targets extracellular tau propagation—the process by which pathological tau spreads between neurons. By developing antibodies or engineered proteins that selectively recognize and neutralize tau "seeds" (the infectious conformational intermediates), this approach aims to block the spread of tau pathology before it establishes new foci in the brain.
Tau pathology follows a predictable spatial pattern in Alzheimer's disease:
- Braak staging: Pathology begins in entorhinal cortex, spreads to hippocampus, then cortex
- Trans-synaptic spread: Pathological tau moves between connected neurons
- Template-driven: Extracellular tau "seeds" convert normal tau to pathological forms
Tau "seeds" are small, misfolded oligomeric forms that:
- Are highly aggregation-prone
- Can template normal tau into pathological conformations
- Are secreted via exosomes and other mechanisms
- Represent the most toxic form of tau pathology
Different tau conformations exist:
- Monomers: Normal, functional tau
- Oligomers: Toxic, intermediate aggregation states
- Filaments: Paired helical filaments (PHFs) and straight filaments (SFs)
- Seeds: The minimal infectious unit that templates aggregation
Antibodies targeting seeds must discriminate between:
- Normal extracellular tau (function unknown, possibly protective)
- Pathological seeds (toxic, must be neutralized)
| Dimension |
Score |
Rationale |
| Novelty |
9 |
Conformational selectivity is a frontier in tau immunotherapy |
| Mechanistic Rationale |
9 |
Targets a well-validated mechanism of tau spread |
| Root-Cause Coverage |
8 |
Addresses propagation, a key driver of disease progression |
| Delivery Feasibility |
7 |
Requires CNS-penetrant biologics or novel delivery |
| Safety Plausibility |
8 |
Similar profile to existing tau antibodies |
| Combinability |
9 |
Synergistic with intracellular tau-targeting approaches |
| Biomarker Availability |
7 |
Seed-specific assays still in development |
| De-risking Path |
7 |
Regulatory pathway established by similar programs |
| Multi-disease Potential |
9 |
Applicable to AD, PSP, CBD, and other tauopathies |
| Patient Impact |
8 |
Blocking spread could significantly alter disease trajectory |
- Screen for antibodies/proteins with seed-selectivity
- Characterize binding to different tau conformations
- Validate in cell-based seeding assays
¶ Antibody Engineering
- Humanize and affinity-mature lead candidates
- Engineer Fc region for optimal effector function
- Consider bispecific designs for enhanced brain penetration
- Passive immunization: IV antibody administration
- Active immunization: Tau vaccine with seed-selective epitopes
- Intracellular delivery: AAV-encoded antibodies or intrabodies
- With anti-aggregation drugs: Block both spread and intracellular accumulation
- With microtubule stabilizers: Protect neurons from tau-mediated toxicity
- With neurotrophic factors: Support neuron survival during treatment
- Develop seed-selective binding assays
- Test in tau seeding mouse models (e.g., PS19)
- Demonstrate reduction in tau propagation
- Phase 1 safety in healthy volunteers
- Phase 2 efficacy signal in early AD or PSP
- Biomarker development in parallel
- Use tau PET as endpoint in early trials
- Pursue accelerated approval in PSP
- Consider biomarker-based patient selection
- Conformational selectivity: Engineering truly seed-selective binders is technically challenging
- Brain penetration: Antibodies have limited CNS exposure
- Timing: Treatment may be most effective in early disease stages
- Biomarkers: Seed-specific biomarkers are needed for patient selection
- Seed-selective antibody screening: Use phage display or single B cell cloning from AD/PSP patients to identify antibodies that distinguish tau seeds from monomers/filaments. Use established seeding assays (Biosciences) for validation.
- Exosomal tau seed capture: Develop affinity columns or magnetic beads with seed-selective ligands to capture and quantify exosomal tau seeds from patient CSF. Compare with tau PET and clinical outcomes.
- Blood-brain barrier penetration optimization: Test antibody engineering approaches (e.g., Fc engineering, bispecific designs, Trojan horse fusion proteins) in in vitro BBB models.
- Patient enrichment strategy: Select participants with early AD (MMSE ≥24) and positive tau PET but limited cortical tau burden (RMC1/2 eligibility criteria). Use CSF or blood tau seed assays for stratification if available.
- Phase 1b design: Single ascending dose in 40 participants with biomarker cohort. Primary endpoint: safety. Secondary: CSF tau species, tau PET change at 12 months.
- Adaptive Phase 2/3: Platform trial design with multiple dose arms and biomarker-stratified randomization. Include PSP arm for regulatory pathway.
- AC Immune: Their anti-tau antibodies (ACI-35, ACI-12589) demonstrate industry capability. Potential licensing or co-development.
- AbbVie/Eli Lilly: Both have tau programs; discuss seed-selective approach.
- Prothelia/ALzheon: Biomarker expertise for patient selection.
- University labs: Dr. Marc Hyman (UCLA), Dr. John Trojanowski (UPenn), Dr. Virginia Lee (UPenn) for academic collaborations.
- NIH R21 (NIA): "Conformational-selective tau seed antibodies for interception therapy"
- NIH U01 (NIA): "Tau seed biomarker development for clinical trials"
- ADRG: "Exosomal tau seeds as predictive biomarker in Alzheimer's disease"
- BrightFocus Foundation: "Antibody engineering for CNS penetration"
Cost: $3-5M
| Milestone |
Timeline |
Cost |
Risk |
| Tau-seed conformational antibody library screening |
Months 1-8 |
$1.5M |
Medium |
| Lead antibody affinity/selectivity optimization |
Months 6-14 |
$1M |
Medium |
| In vitro tau-seed clearance assay development |
Months 10-16 |
$800K |
Low |
| Pre-IND meeting with FDA |
Month 14 |
$200K |
Low |
| IND-enabling toxicology initiation |
Months 14-18 |
$700K |
Low |
Key Risks:
- Conformational selectivity may be difficult to achieve (mitigation: screen large antibody library)
- Tau-seed variants may differ between patients (mitigation: test against multiple patient-derived seeds)
Cost: $10-18M
| Milestone |
Timeline |
Cost |
Risk |
| Phase 1 dose-escalation (n=24) |
Months 16-24 |
$3M |
Low |
| Phase 2a efficacy signal detection (n=60) |
Months 20-32 |
$7M |
Medium |
| Tau-seed biomarker assay validation |
Months 18-28 |
$2M |
Medium |
| Interim analysis |
Month 28 |
$500K |
Medium |
| Phase 2b dose selection |
Month 34 |
$1.5M |
Low |
Key Risks:
- First-in-class mechanism may have unexpected safety signals
- Tau-seed biomarker may not correlate with clinical endpoints
Cost: $40-60M
| Milestone |
Timeline |
Cost |
Risk |
| Global Phase 3 protocol design |
Months 32-36 |
$3M |
Low |
| Enrollment (n=800-1000) |
Months 36-50 |
$30M |
Medium |
| Phase 3 readout |
Month 56 |
$6M |
Medium |
| Regulatory submissions |
Months 56-60 |
$10M |
Low |
| Scenario |
Probability |
Cost Impact |
| Best case (accelerated) |
15% |
$40M |
| Base case |
50% |
$65M |
| Slow enrollment |
25% |
$85M |
| Safety signal |
10% |
+$30M |
- US: Banner Sun Health (largest AD brain bank), Washington University (DIAN), UCI MIND
- EU: University of Cambridge, Karolinska Institutet, Amsterdam UMC
- Key Opinion Leaders: Dr. Marc H. Smith (Tau biology), Dr. Colin Masters (AD biomarkers)
| Gate |
Criteria |
Go/No-Go |
| Phase 1→2 |
Safety + PK/PD |
Go if MTD reached |
| Phase 2→3 |
Tau-seed reduction + cognition signal |
Go if >25% slowing |
| Registration |
Phase 3 confirmatory |
Go if p<0.01 |
| Dimension |
Score |
Rationale |
| Novelty |
8/10/10 |
Tau seed interception is novel; targets propagation mechanism |
| Mechanistic Rationale |
8/10/10 |
Blocks tau spread between neurons; targets oligomeric forms |
| Addresses Root Cause |
8/10/10 |
Addresses tau propagation - key pathological mechanism |
| Delivery Feasibility |
6/10/10 |
Antibody or small molecule; brain penetration needed |
| Safety Plausibility |
7/10/10 |
Targeted approach; minimal off-target expected |
| Combinability |
8/10/10 |
Excellent combination with tau aggregation inhibitors |
| Biomarker Availability |
7/10/10 |
Tau PET and CSF biomarkers available; seed detection developing |
| De-risking Path |
7/10/10 |
Antibody approaches advancing; small molecules in development |
| Multi-disease Potential |
8/10/10 |
Relevant for AD, CTE, primary tauopathies |
| Patient Impact |
8/10/10 |
Could halt disease progression by blocking tau spread |
| Total |
75/100 |
|
- Immunotherapy — conformational-selective antibodies are the core of this approach
- Tau-Targeted Therapeutics — broader tau-targeting strategies
- Tau Pathology — core pathological mechanism being targeted
- Protein Aggregation — seed formation is an aggregation phenomenon
- Exosome-Mediated Propagation — tau seeds spread via exosomes